• Explore /
  • Poster
  • / CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).

CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).

Abstract Poster

Authors

null

Eunice S. Wang

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

Eunice S. Wang , Lionel Adés , Amir Tahmasb Fathi , Karl A Kreuzer , Megan Marie O'Meara , Shang-Ying Liang , Farhad Ravandi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02785900

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS7066)

DOI

10.1200/JCO.2017.35.15_suppl.TPS7066

Abstract #

TPS7066

Poster Bd #

266a

Abstract Disclosures

Similar Posters

First Author: Jalaja Potluri

First Author: Amy Elizabeth Dezern

Poster

2020 ASCO Virtual Scientific Program

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.

First Author: Brian Andrew Jonas

First Author: Guillermo Garcia-Manero